,14 Importantly, the prospect of translating MIP1α HA mix vaccines to humans is promising, as human MIP1α (LD78b) has been shown to enhance immune responses in mice,16 and since LD78b was used in promising phase 1/2a studies in women with cervical intraepithelial neoplasia17 and advanced cervical cancer.18 This evidence concerns the gene CCL3 and cervical carcinoma.